newsfilter
← Latest News
GlobeNewswire·

Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer

  • Telomir Pharmaceuticals, Inc. has selected Linical, a global CRO with extensive oncology experience, to support its FDA-cleared Phase 1/2 clinical trial evaluating Telomir-Zn in patients with advanced or metastatic triple-negative breast cancer.
  • The Company executed a Master Services Agreement & clinical trial Work Order with Linical to establish the operational framework for the study.
  • Clinical initiation for the trial is targeted for the first quarter of 2027.
  • The engagement follows the U.S. Food and Drug Administration's clearance of Telomir's Investigational New Drug application.
  • Linical brings over two decades of experience in oncology, with approximately half of its portfolio focused on early-phase studies & breast cancer research.
  • Telomir-Zn is an investigational oral epigenetic therapy designed to regulate intracellular metal homeostasis & potentially reactivate silenced tumor suppressor genes involved in cancer growth.
  • The upcoming trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, & preliminary antitumor activity of Telomir-Zn as a monotherapy.
  • Preclinical research demonstrated antitumor activity in TNBC models, supporting further investigation of the therapy in cancers with elevated iron dependency.
Company
Telomir Pharmaceuticals, Inc.
Keywords
Nasdaq:TELO, Telomir Pharmaceuticals, Inc., $TELO, Telomir Pharmaceuticals, Telomir-Zn, Linical, Triple-Negative Breast Cancer, TNBC, CRO Selection, Clinical Trial Partnership